PET imaging trial partnerships
Oncology PET trial imaging, under one contract
Amavita Research is a clinical trial site and PET imaging trial partner. Our North Miami Beach site runs cardiovascular trials; for oncology trials where PET imaging drives eligibility and response, we contract as the prime imaging-trial partner — one contract, one project manager, PET delivered through our qualified imaging network.
Modern oncology trials increasingly hinge on molecular imaging. PSMA PET gates eligibility for prostate radioligand therapy. FAPI and FDG PET define response. Dosimetry imaging is the readout itself in alpha- and beta-particle programs. When imaging is the trial, fragmented imaging vendors become the critical path — and the risk.
Amavita Research removes that risk by contracting as the prime imaging-trial partner. Sponsors sign one contract with one accountable owner: feasibility, budget, imaging charter adherence, DICOM transfer and QC, and monitor access all run through a single project manager and a single PI team. PET imaging executes through our qualified imaging network — PET/CT, F-18/N-13 tracer capability, GCP and 21 CFR Part 11 controls.
This is the same operating discipline behind our cardiovascular site: 7 active trials, GCSA-certified through February 2027, and a last program that went from CTA to first-patient-in in 41 days. We bring that startup speed and audit-ready process to PET-centric oncology programs.
PET tracers and modalities we coordinate
- PSMA PET (Ga-68 / F-18) — prostate cancer eligibility and response
- FAPI PET — fibroblast-activation imaging across solid tumors
- FDG PET/CT — staging, response assessment, and metabolic readouts
- F-18 and N-13 tracer capability coordinated through the imaging network
Radioligand therapy trial support
- Alpha-particle (Ac-225 class) and beta-particle (Lu-177 class) therapy programs
- Dosimetry imaging as a primary or secondary readout
- Eligibility-gated imaging: PET-driven patient selection per protocol
- Imaging charter adherence, reader workflow coordination, and DICOM QC
What sponsors get
- One contract, one project manager, one PI team
- Feasibility in days, with a 20-minute sponsor consultation led by our COO
- GCP-compliant imaging operations with 21 CFR Part 11 controls
- Audit-ready documentation from a GCSA-certified organization
How the prime model works
| Dimension | Amavita Research |
|---|---|
| Contracting | Amavita is the prime contractor to the sponsor. Imaging executes as a qualified subcontracted workstream — no direct sponsor-to-imaging-vendor contracting. |
| Accountability | One project manager owns feasibility, budget, imaging reads, and monitor access. Enrollment through imaging reads runs under one team. |
| Imaging delivery | PET imaging delivered through our qualified imaging network — PET/CT acquisition, tracer coordination, per-charter reads, DICOM transfer and QC. |
| Patient enrollment | Cardiovascular enrollment happens at our North Miami Beach site. For oncology PET trials, Amavita serves as the prime imaging-trial partner, not the enrolling site. |
| Quality | GCSA-certified through February 2027. GCP and 21 CFR Part 11 controls on imaging data. Zero FDA Form 483 findings to date. |
Frequently asked questions
Does Amavita enroll oncology patients at its North Miami Beach site?
No. Our North Miami Beach site enrolls cardiovascular trials. For oncology trials, Amavita contracts as the prime imaging-trial partner: we own the sponsor contract, project management, and imaging coordination, with PET imaging delivered through our qualified imaging network.
What does 'prime imaging-trial partner' mean for our CTA?
The sponsor signs one clinical trial agreement with Amavita Research Services. Amavita owns contracting, invoicing, project management, and the imaging workstream. Imaging sites operate as qualified subcontractors under Amavita's oversight — the sponsor never has to contract or manage them directly.
Which oncology PET modalities can you support?
PSMA PET (Ga-68/F-18) for prostate programs, FAPI PET, FDG PET/CT, F-18 and N-13 tracer coordination, and dosimetry imaging for radioligand therapy trials (Ac-225 and Lu-177 class), all executed per the study imaging charter through our qualified imaging network.
How fast can we get a feasibility assessment?
Our COO, Nereisy Alonso, leads a 20-minute feasibility consultation for sponsors. Our last program went from CTA to first-patient-in in 41 days, and we target contract turnaround in days, not quarters.
Who owns the sponsor relationship?
Amavita does. Sponsor consultations, feasibility, and operational follow-through are owned by Nereisy Alonso, COO. One contact, same-business-day response.
Next step
Schedule a 20-minute feasibility call
Talk with Nereisy Alonso, COO — she owns all sponsor consultations. Feasibility, budget, contracts, and monitor access from a single owner, with same-business-day response.